MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives

[1]  John T. Dimos,et al.  Axonal Charcot–Marie–Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties , 2015, Experimental Neurology.

[2]  C. O'brien,et al.  Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases. , 2015, New biotechnology.

[3]  C. Siskind.  Charcot Marie Tooth , 2015 .

[4]  P. Chinnery,et al.  Disturbed mitochondrial dynamics and neurodegenerative disorders , 2015, Nature Reviews Neurology.

[5]  Wenzhang Wang,et al.  MFN2 Couples Glutamate Excitotoxicity and Mitochondrial Dysfunction in Motor Neurons*♦ , 2014, The Journal of Biological Chemistry.

[6]  J. Puyal,et al.  Mfn2 downregulation in excitotoxicity causes mitochondrial dysfunction and delayed neuronal death , 2014, The EMBO journal.

[7]  P. Agostinis,et al.  New functions of mitochondria associated membranes in cellular signaling. , 2014, Biochimica et biophysica acta.

[8]  F. Bombelli,et al.  Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features. , 2014, JAMA neurology.

[9]  L. Dupuis.  Mitochondrial quality control in neurodegenerative diseases. , 2014, Biochimie.

[10]  I. Scott,et al.  Regulation of autophagy and mitophagy by nutrient availability and acetylation. , 2014, Biochimica et biophysica acta.

[11]  Kwong Wai Choy,et al.  Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. , 2014, Gene.

[12]  Z. Sheng,et al.  Mitochondrial trafficking and anchoring in neurons: New insight and implications , 2014, The Journal of cell biology.

[13]  Jonas Christoffersson,et al.  Autophagy and apoptosis dysfunction in neurodegenerative disorders , 2014, Progress in Neurobiology.

[14]  M. Lucchetta,et al.  Novel mutation of the mitofusin 2 gene in a family with Charcot–Marie–Tooth disease type 2 , 2014, Muscle & nerve.

[15]  L. Petrucelli,et al.  The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. , 2013, Human molecular genetics.

[16]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[17]  J. Millán,et al.  Charcot-Marie-Tooth disease , 2013, Neurology.

[18]  S. Mellgren,et al.  Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies , 2013, BMC Medical Genetics.

[19]  S. Lipton,et al.  Dysfunctional Mitochondrial Dynamics in the Pathophysiology of Neurodegenerative Diseases , 2013, Journal of cell death.

[20]  F. Rizzo,et al.  Mitochondrial Fusion Proteins and Human Diseases , 2013, Neurology research international.

[21]  G. Dorn,et al.  PINK1-Phosphorylated Mitofusin 2 Is a Parkin Receptor for Culling Damaged Mitochondria , 2013, Science.

[22]  M. Iijima,et al.  Mitochondrial dynamics in neurodegeneration. , 2013, Trends in cell biology.

[23]  H. Lv,et al.  Mitofusin 2 gene mutation causing early-onset CMT2A with different progressive courses. , 2013, Clinical neuropathology.

[24]  K. Kollewe,et al.  Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion , 2013, Acta Neuropathologica.

[25]  H. McBride,et al.  The intracellular redox state is a core determinant of mitochondrial fusion , 2012, EMBO reports.

[26]  R. Nixon,et al.  Autophagy and neuronal cell death in neurological disorders. , 2012, Cold Spring Harbor perspectives in biology.

[27]  F. Tison,et al.  A French family with Charcot–Marie–Tooth disease related to simultaneous heterozygous MFN2 and GDAP1 mutations , 2012, Neuromuscular Disorders.

[28]  M. Jiang,et al.  A novel mutation of the MFN2 gene in a Chinese family with Charcot-Marie-Tooth disease. , 2012, Genetics and molecular research : GMR.

[29]  Su-Yoen Park,et al.  A novel double mutation in cis in MFN2 causes Charcot–Marie–Tooth neuropathy type 2A , 2012, neurogenetics.

[30]  J. Milbrandt,et al.  Mitofusin2 Mutations Disrupt Axonal Mitochondrial Positioning and Promote Axon Degeneration , 2012, The Journal of Neuroscience.

[31]  R. Youle,et al.  Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. , 2012, Developmental cell.

[32]  J. Pouget,et al.  The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy 'plus' phenotype. , 2012, Brain : a journal of neurology.

[33]  T. Ikeda,et al.  Coenzyme Q10 therapy in hereditary motor sensory neuropathy type VI with novel mitofusin 2 mutation. , 2012, Internal medicine.

[34]  Yi-Chung Lee,et al.  The Mutational Spectrum in a Cohort of Charcot-Marie-Tooth Disease Type 2 among the Han Chinese in Taiwan , 2011, PloS one.

[35]  S. Smaili,et al.  The role of mitochondrial function in glutamate-dependent metabolism in neuronal cells. , 2011, Current pharmaceutical design.

[36]  J. Cunningham,et al.  Large kindred evaluation of mitofusin 2 novel mutation, extremes of neurologic presentations, and preserved nerve mitochondria. , 2011, Archives of neurology.

[37]  T. Pieber,et al.  SNP array-based whole genome homozygosity mapping as the first step to a molecular diagnosis in patients with Charcot-Marie-Tooth disease , 2011, Journal of Neurology.

[38]  M. Sabatelli,et al.  Clinical, electrophysiological and pathological findings of a patient with CMT2 due to the p.Ala738Val mitofusin 2 mutation , 2011, Journal of the Neurological Sciences.

[39]  B. Ceulemans,et al.  Genetic spectrum of hereditary neuropathies with onset in the first year of life , 2011, Brain : a journal of neurology.

[40]  H. Houlden,et al.  Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations , 2011, Neurology.

[41]  E. Schon,et al.  Mitochondria: The Next (Neurode)Generation , 2011, Neuron.

[42]  A. C. Santos,et al.  Characterizing the phenotypic manifestations of MFN2 R104W mutation in Charcot–Marie–Tooth type 2 , 2011, Neuromuscular Disorders.

[43]  F. Kok,et al.  Clinical and neurophysiological investigation of a large family with dominant Charcot-Marie-Tooth type 2 disease with pyramidal signs. , 2011, Arquivos de neuro-psiquiatria.

[44]  S. Sasaki.  Autophagy in Spinal Cord Motor Neurons in Sporadic Amyotrophic Lateral Sclerosis , 2011, Journal of neuropathology and experimental neurology.

[45]  D. Bonneau,et al.  Simultaneous MFN2 and GDAP1 mutations cause major mitochondrial defects in a patient with CMT , 2011, Neurology.

[46]  M. Shy,et al.  MFN2 mutations cause severe phenotypes in most patients with CMT2A , 2011, Neurology.

[47]  P. Vinci,et al.  Anesthetic management in Charcot-Marie-Tooth disease type 2 due to a mutation in the mitofusin-2 gene , 2011, Journal of anaesthesiology, clinical pharmacology.

[48]  K. Hayasaka,et al.  Molecular diagnosis and clinical onset of Charcot–Marie–Tooth disease in Japan , 2011, Journal of Human Genetics.

[49]  C. Gellera,et al.  Co-occurrence of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease type 2A in a patient with a novel mutation in the mitofusin-2 gene , 2011, Neuromuscular Disorders.

[50]  S. Züchner,et al.  Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2 , 2011, Journal of Neurology.

[51]  D. Herrmann.  Experimental therapeutics in hereditary neuropathies: The past, the present, and the future , 2008, Neurotherapeutics.

[52]  R. Youle,et al.  Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin , 2010, The Journal of cell biology.

[53]  A. Schapira,et al.  Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. , 2010, Human molecular genetics.

[54]  S. Vandenberg,et al.  Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. , 2010, The Journal of clinical investigation.

[55]  G. Comi,et al.  Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells , 2010, Cellular and Molecular Life Sciences.

[56]  B. Suh,et al.  Early-onset Charcot-Marie-Tooth patients with mitofusin 2 mutations and brain involvement , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[57]  F. Boaretto,et al.  SEVERE CMT TYPE 2 WITH FATAL ENCEPHALOPATHY ASSOCIATED WITH A NOVEL MFN2 SPLICING MUTATION , 2010, Neurology.

[58]  J. Gal,et al.  Mitochondrial dysfunction is a converging point of multiple pathological pathways in amyotrophic lateral sclerosis. , 2010, Journal of Alzheimer's disease : JAD.

[59]  C. Ching,et al.  A novel mitofusin 2 gene mutation causing Charcot-Marie-Tooth type 2A disease in a Chinese family. , 2010, Chinese medical journal.

[60]  D. Chudakov,et al.  Human Miltons associate with mitochondria and induce microtubule-dependent remodeling of mitochondrial networks. , 2010, Biochimica et biophysica acta.

[61]  J. Milbrandt,et al.  Mitofusin 2 Is Necessary for Transport of Axonal Mitochondria and Interacts with the Miro/Milton Complex , 2010, The Journal of Neuroscience.

[62]  R. Krüger,et al.  Reduced Basal Autophagy and Impaired Mitochondrial Dynamics Due to Loss of Parkinson's Disease-Associated Protein DJ-1 , 2010, PloS one.

[63]  M. Russell,et al.  MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families , 2010, BMC Medical Genetics.

[64]  K. Xia,et al.  [Mutation analysis of MFN2 gene in Chinese patients with Charcot-Marie-Tooth disease]. , 2009, Zhonghua yi xue za zhi.

[65]  A. Toutain,et al.  Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. , 2009, Archives of neurology.

[66]  Xiaomin Song,et al.  Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice , 2009, Proceedings of the National Academy of Sciences.

[67]  D. Bonneau,et al.  Phenotypic spectrum of MFN2 mutations in the Spanish population , 2009, Journal of Medical Genetics.

[68]  D. Chan,et al.  Mitochondrial dynamics–fusion, fission, movement, and mitophagy–in neurodegenerative diseases , 2009, Human molecular genetics.

[69]  M. Martin-Négrier,et al.  Ultrastructural mitochondrial modifications characteristic of mitofusin 2 mutations (CMT2A) , 2009, Journal of the peripheral nervous system : JPNS.

[70]  Z. Sheng,et al.  Dynein Light Chain LC8 Regulates Syntaphilin-Mediated Mitochondrial Docking in Axons , 2009, The Journal of Neuroscience.

[71]  B. Gentil,et al.  Mitochondrial and Axonal Abnormalities Precede Disruption of the Neurofilament Network in a Model of Charcot-Marie-Tooth Disease Type 2E and Are Prevented by Heat Shock Proteins in a Mutant-Specific Fashion , 2009, Journal of neuropathology and experimental neurology.

[72]  S. Ajroud‐Driss,et al.  A novel de novo MFN2 mutation causing CMT2A with upper motor neuron signs , 2009, neurogenetics.

[73]  G. Hajnóczky,et al.  Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase , 2008, Proceedings of the National Academy of Sciences.

[74]  N. Bresolin,et al.  Mutated mitofusin 2 presents with intrafamilial variability and brain mitochondrial dysfunction , 2008, Neurology.

[75]  V. Volpini,et al.  Two Spanish families with Charcot–Marie–Tooth type 2A: Clinical, electrophysiological and molecular findings , 2008, Neuromuscular Disorders.

[76]  A. B. Knott,et al.  Impairing the Mitochondrial Fission and Fusion Balance: A New Mechanism of Neurodegeneration , 2008, Annals of the New York Academy of Sciences.

[77]  R. Youle,et al.  Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.

[78]  J. Pollard,et al.  Histopathological Findings in Hereditary Motor and Sensory Neuropathy of Axonal Type With Onset in Early Childhood Associated With Mitofusin 2 Mutations , 2008, Journal of neuropathology and experimental neurology.

[79]  A. Grierson,et al.  Role of axonal transport in neurodegenerative diseases. , 2008, Annual review of neuroscience.

[80]  J. Vallat,et al.  Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations , 2008, Neurology.

[81]  P. Dechent,et al.  Cerebral involvement in axonal Charcot-Marie-Tooth neuropathy caused by mitofusin2 mutations , 2008, Journal of Neurology.

[82]  R. Baloh,et al.  Mitochondrial Dynamics and Peripheral Neuropathy , 2008, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[83]  W. Le,et al.  Altered macroautophagy in the spinal cord of SOD1 mutant mice , 2008, Autophagy.

[84]  L. Scorrano,et al.  Mitofusin 2: a mitochondria-shaping protein with signaling roles beyond fusion. , 2008, Antioxidants & redox signaling.

[85]  Cuiling Li,et al.  Docking of Axonal Mitochondria by Syntaphilin Controls Their Mobility and Affects Short-Term Facilitation , 2008, Cell.

[86]  M. Cairns,et al.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. , 2007, The American journal of pathology.

[87]  M. Wood,et al.  Modulating the Expression of Disease Genes with RNA-Based Therapy , 2007, PLoS genetics.

[88]  T. Eggermann,et al.  Mitofusin 2 gene mutation (R94Q) causing severe early‐onset axonal polyneuropathy (CMT2A) , 2007, European journal of neurology.

[89]  C. Ki,et al.  Mitochondrial GTPase mitofusin 2 mutations in Korean patients with Charcot‐Marie‐Tooth neuropathy type 2 , 2007, Clinical genetics.

[90]  D. Chan,et al.  Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations , 2007, The Journal of cell biology.

[91]  A. Pestronk,et al.  Altered Axonal Mitochondrial Transport in the Pathogenesis of Charcot-Marie-Tooth Disease from Mitofusin 2 Mutations , 2007, The Journal of Neuroscience.

[92]  S. Züchner,et al.  Molecular genetics of autosomal-dominant axonal Charcot-Marie-Tooth disease , 2007, NeuroMolecular Medicine.

[93]  M. Shy.  Therapeutic strategies for the inherited neuropathies , 2007, NeuroMolecular Medicine.

[94]  E. Masliah,et al.  Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases , 2007, NeuroMolecular Medicine.

[95]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[96]  L. Goldstein,et al.  The Genetics of Axonal Transport and Axonal Transport Disorders , 2006, PLoS genetics.

[97]  D. Chan,et al.  Critical dependence of neurons on mitochondrial dynamics. , 2006, Current opinion in cell biology.

[98]  J. Lupski,et al.  MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. , 2006, Brain : a journal of neurology.

[99]  J. Hwang,et al.  Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. , 2006, Brain : a journal of neurology.

[100]  M. Vorgerd,et al.  Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2) , 2006, BMC Medical Genetics.

[101]  F. Baas,et al.  Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2 , 2006, Annals of neurology.

[102]  D. Chan,et al.  Emerging functions of mammalian mitochondrial fusion and fission. , 2005, Human molecular genetics.

[103]  K. Flanigan,et al.  Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene , 2005, Neurology.

[104]  H. McBride,et al.  Activated Mitofusin 2 Signals Mitochondrial Fusion, Interferes with Bax Activation, and Reduces Susceptibility to Radical Induced Depolarization*[boxs] , 2005, Journal of Biological Chemistry.

[105]  J. McCaffery,et al.  Structural Basis of Mitochondrial Tethering by Mitofusin Complexes , 2004, Science.

[106]  M. Tarnopolsky,et al.  Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription. , 2004, Archives of physical medicine and rehabilitation.

[107]  Michael P. Sheetz,et al.  Axonal mitochondrial transport and potential are correlated , 2004, Journal of Cell Science.

[108]  M. Pericak-Vance,et al.  Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A , 2004, Nature Genetics.

[109]  G. Melli,et al.  Sensory manifestations in Charcot‐Marie‐Tooth disease , 2000, Journal of the peripheral nervous system : JPNS.

[110]  K. Hayasaka,et al.  Mitochondrial GTPase mitofusin 2 mutation in Charcot–Marie–Tooth neuropathy type 2A , 2004, Human Genetics.

[111]  S. Vucic,et al.  CMT with pyramidal features , 2003, Neurology.

[112]  Erik E. Griffin,et al.  Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development , 2003, The Journal of cell biology.

[113]  F. Gemignani,et al.  Charcot–Marie–Tooth disease (CMT): distinctive phenotypic and genotypic features in CMT type 2 , 2001, Journal of the Neurological Sciences.

[114]  A. Quattrone,et al.  Clinical and genetic study of a large Charcot–Marie–Tooth type 2A family from southern Italy , 2001, Neurology.

[115]  S. Tsuji,et al.  Linkage mapping of the gene for Charcot-Marie-Tooth disease type 2 to chromosome 1p (CMT2A) and the clinical features of CMT2A , 1997, Neurology.

[116]  A. Gatherer,et al.  Sarcoma of the Larynx , 1958, The Journal of Laryngology & Otology.

[117]  A. Bird,et al.  Autosomal dominant optic atrophy with asymptomatic peripheral neuropathy. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[118]  J. Siedow,et al.  Partial Purification of the Cyanide-Resistant Alternative Oxidase of Skunk Cabbage (Symplocarpus foetidus) Mitochondria , 1993, Plant physiology.

[119]  F. Gabreëls,et al.  Hereditary motor and sensory neuropathy of neuronal type with onset in early childhood , 1991, Clinical Neurology and Neurosurgery.